Browsing by Author Maggioni, Aldo

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2009Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT)Caterson, Ian; Bacher, H; Coutinho, Walmir; Finer, Nick; James, W; Maggioni, Aldo; Sharma, Arya; Shepherd, Gillian; Torp-Pedersen, Christian; Van Gaal, L; Boden InstituteBlood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT), Diabetes, Obesity and Metabolism, vol.11, N/A, 2009,pp 239-250
2015Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trialCaterson, Ian; Espinoza, David; Gebski, Val; Seimon, Radhika; Sweeting, Arianne Natasha; Coutinho, Walmir; Finer, Nick; James, W; Legler, U F; Maggioni, Aldo; Sharma, Arya; Torp-Pedersen, Christian; Van Gaal, Luc; Boden Institute; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Boden Institute; Boden InstituteChanges in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial, International Journal of Obesity, vol.39, 5, 2015,pp 849-857
2010Early Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in PeriodCaterson, Ian; Coutinho, Walmir; Finer, Nick; Ge, Hong; James, Philip; Maggioni, Aldo; Santoro, Donatella; Sharma, Arya; Shepherd, Gillian; Torp-Pedersen, Christian; Van Gaal, Luc; Boden InstituteEarly Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in Period, Obesity, vol.18, 5, 2010,pp 987-994
2012Maintained Intentional Weight Loss Reduces Cardiovascular Outcomes: Results from the Sibutramine Cardiovascular OUTcomes (SCOUT) TrialCaterson, Ian; Coutinho, Walmir; et al, various; Finer, Nick; Legler, U; Maggioni, Aldo; Rode, Richard; Sharma, Arya; Shepherd, Gillian; Torp-Pedersen, Christian; Van Gaal, Luc; Molecular BioscienceMaintained Intentional Weight Loss Reduces Cardiovascular Outcomes: Results from the Sibutramine Cardiovascular OUTcomes (SCOUT) Trial, Diabetes, Obesity and Metabolism, vol.14, 6, 2012,pp 523-530
2017Relation between weight loss and causes of death in patients with cardiovascular disease: Finding from the SCOUT trialCaterson, Ian; Seimon, Radhika; Sweeting, Arianne Natasha; Coutinho, Walmir; Finer, Nick; James, W; Legler, U; Maggioni, Aldo; Sharma, Arya; Torp-Pedersen, Christian; Urso, Renato; Van Gaal, Luc; Boden Institute; Boden Institute; Boden InstituteRelation between weight loss and causes of death in patients with cardiovascular disease: Finding from the SCOUT trial, Journal of Cardiovascular Medicine (Hagerstown), vol.18, 3, 2017,pp 144-151
2012Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetesCaterson, Ian; Andersson, Charlotte; Couthino, W.; Finer, Nick; James, W; Maggioni, Aldo; Sharma, Arya; Torp-Pedersen, Christian; Van Gaal, L; Weeke, Peter; Boden InstituteRelationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes, Diabetologia: clinical and experimental diabetes and metabolism, vol.55, 9, 2012,pp 2348-2355
2008Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) TrialCaterson, Ian; Bacher, Peter; Coutinho, Walmir; Finer, Nick; James, Philip; Maggioni, Aldo; Sharma, Arya; Shepherd, Gillian; Sun, Rui; Torp-Pedersen, Christian; Van Gaal, Luc; Boden InstituteTolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial, Journal of Cardiovascular Pharmacology, vol.52, 5, 2008,pp 393-402